Los receptores epidérmicos humanos en el cáncer gástrico: alteraciones moleculares y su papel como diana terapéutica.

Autor:	Bustos-Carpinteyro AR; División de Genética, Centro de Investigación Biomédica de Occidente, Instituto Mexicano del Seguro Social; México.; Doctorado en Genética Humana, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara. Guadalajara, Jal.; México., Magaña-Torres MT; División de Genética, Centro de Investigación Biomédica de Occidente, Instituto Mexicano del Seguro Social; México., González-García JR; División de Genética, Centro de Investigación Biomédica de Occidente, Instituto Mexicano del Seguro Social; México., Torres-Jasso JH; Departamento de Ciencias Biológicas, División de Ciencias Biológicas y de la Salud, Centro Universitario de la Costa, Universidad de Guadalajara, Delegación Ixtapa, Puerto Vallarta, Jal. México., Sánchez-López JY; División de Genética, Centro de Investigación Biomédica de Occidente, Instituto Mexicano del Seguro Social; México.
Jazyk:	angličtina
Zdroj:	Gaceta medica de Mexico [Gac Med Mex] 2017; Vol. 153 (7), pp. 830-840.
DOI:	10.24875/GMM.17002748
Abstrakt:	Gastric cancer (GC) is the third leading cause of cancer death worldwide; both environmental and genetic factors are involved in the etiology of this neoplasia. The human epidermal receptor (HER) pathway is essential for proliferation and differentiation of normal cells; but it is also implicated in the growth of cancer cells. In this work we investigate the molecular alterations in genes that encodes for HER receptors reported in GC, as well the role as therapeutic targets. We reviewed the literature reported to date regarding overexpression of HER-receptors, amplification and somatic mutations in ERBB genes occurred in gastric tumors, as well as the anti-HER therapies tested for treatment of GC. In GC, the overexpression of HER family is reported in a range of 12-87% of cases; up to 67% of cases with amplification, and 90 somatic mutations in ERBB genes. The only drug anti-HER approved for using combined with chemotherapy, in treatment of patients with advanced GC is trastuzumab; however, other targeted therapies are being investigated. The role of the HER family as a therapeutic target has not shown significant improvements in recent years; hence, further studies are required to find better options for treatment of GC. (Copyright: © 2017 SecretarÍa de Salud.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu